Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | CASP1 | P29466 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.45 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13254985 | 1.00 | TDP1 (0.48) | TDP1ALDH1A1CASP1MAPTGAA | |
| SCHEMBL13254987 | 1.00 | TDP1 (0.48) | TDP1ALDH1A1CASP1MAPTGAA | |
| SCHEMBL21449156 | 0.84 | ALDH1A1 (0.50) | TDP1ALDH1A1CASP1MAPTGAA | |
| SCHEMBL512377 | 0.82 | ALDH1A1 (0.59) | TDP1ALDH1A1CASP1MAPTGAA | |
| SCHEMBL18422677 | 0.82 | ALDH1A1 (0.48) | TDP1ALDH1A1MAPTGAAHIF1A | |
| SCHEMBL4368719 | 0.80 | ALDH1A1 (0.50) | TDP1ALDH1A1CASP1MAPTGAA | |
| SCHEMBL11804318 | 0.80 | ALDH1A1 (0.50) | TDP1ALDH1A1CASP1MAPTGAA | |
| Hydrochloric Acid SCHEMBL11333307 | 0.80 | ALDH1A1 (0.57) | TDP1ALDH1A1CASP1MAPTGAA | |
| SCHEMBL16392261 | 0.80 | ALDH1A1 (0.50) | TDP1ALDH1A1CASP1MAPTGAA | |
| SCHEMBL15854546 | 0.80 | PTPN5 (0.47) | TDP1ALDH1A1CASP1MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288552-B2 | Dihydropyridone amidesas P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2012-10-16 | — | — | US | claimed |
| EP-2651899-B1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2017-05-31 | — | — | EP | disclosed |
| US-8815903-B2 | Indole derivative and pharmacologically acceptable salt thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2014-08-26 | — | — | US | disclosed |
| EP-2669272-A1 | INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT OF SAME | Kissei Pharmaceutical Co., Ltd. (JP) | 2013-12-04 | — | — | EP | disclosed |
| US-20130317065-A1 | INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL COMPANY, LIMITED (JP) | 2013-11-28 | — | — | US | disclosed |
| EP-1037887-B1 | 5-(2-IMIDAZOLINYLAMINO)-BENZIMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS .ALPHA.-ADRENOCEPTOR AGONISTS WITH IMPROVED METABOLIC STABILITY | PROCTER & GAMBLE (US) | 2004-07-14 | — | — | EP | disclosed |
| US-6486190-B1 | 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability | THE PROCTER & GAMBLE COMPANY | 2002-11-26 | — | — | US | disclosed |
| CN-1284073-A | 5- (2-imidazolinylamino) -benzimidazole derivatives, their preparation and their use as alpha-adrenergic receptor agonists with improved metabolic stability | PROCTER & GAMBLE (US) | 2001-02-14 | — | — | CN | disclosed |
| EP-1037887-A1 | 5-(2-IMIDAZOLINYLAMINO)-BENZIMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS .ALPHA.-ADRENOCEPTOR AGONISTS WITH IMPROVED METABOLIC STABILITY | THE PROCTER & GAMBLE COMPANY (US) | 2000-09-27 | — | — | EP | disclosed |
| WO-1999026942-A1 | 5-(2-IMIDAZOLINYLAMINO)-BENZIMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS .ALPHA.-ADRENOCEPTOR AGONISTS WITH IMPROVED METABOLIC STABILITY | THE PROCTER & GAMBLE COMPANY (US) | 1999-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130317065-A1 | INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | PTGER1, CYSLTR1, LTB4R | TDP1 4350/4885ALDH1A1 902/4885CASP1 2771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.